Source comparison
MK-677 Long Term Studies: Safety Signal Comparison
Chapman et al. (1996) 12 months 32 healthy elderly +78% at month 12 6% (edema, joint stiffness) +5 mg/dL +1.8% Proof-of-concept for sustained IGF-1 elevation but insufficient power for safety endpoints Murphy et al. (1999) 24 obese males +72% at month 6, +65%
This comparison does not assign a generated winner or score.
- Chapman et al. (1996)
- 12 months
- 32 healthy elderly
- +78% at month 12
- 6% (edema, joint stiffness)
- +5 mg/dL
- +1.8%
- Proof-of-concept for sustained IGF-1 elevation but insufficient power for safety endpoints
- Murphy et al. (1999)
- 24 obese males
- +72% at month 6, +65% at month 12
- 12% (glucose intolerance)
- +8 mg/dL
- Not assessed
- First trial to document significant glycemic worsening. Subjects with baseline IR excluded but still showed effect
- Nass et al. (2008)
- 24 months
- 65 hip fracture patients
- +84% at month 12, +69% at month 24
- 9% (hyperglycemia, edema)
- +6 mg/dL
- +3.3%
- Longest trial on record but excluded high-risk populations and lacked post-treatment follow-up
- Svensson et al. (1998)
- 9 months
- 24 GH-deficient adults
- +112% at month 6
- 17% (fluid retention, paresthesia)
- +4 mg/dL
- +2.1%
- Demonstrated supraphysiological IGF-1 response in pathological GH deficiency. Not generalizable to healthy users